推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 根據(jù)《國務(wù)院關(guān)于取消和調(diào)整一批行政審批項目等事項的決定》(國發(fā)〔2016〕10號)，取消中藥材生產(chǎn)質(zhì)量管理規(guī)范(以下簡稱中藥材gap)認證行政許可事項。為進一步做好中藥材gap監(jiān)督實施工作，現(xiàn)就有關(guān)事宜公告如下：
一、自公告發(fā)布之日起，國家食品藥品監(jiān)督管理總局不再開展中藥材gap認證工作，不再受理相關(guān)申請。
二、國家食品藥品監(jiān)督管理總局將繼續(xù)做好取消認證后中藥材gap的監(jiān)督實施工作，對中藥材gap實施備案管理，具體辦法另行制定。
三、已經(jīng)通過認證的中藥材生產(chǎn)企業(yè)應(yīng)繼續(xù)按照中藥材gap規(guī)定，切實加強全過程質(zhì)量管理，保證持續(xù)合規(guī)。食品藥品監(jiān)督管理部門要加強中藥材gap的監(jiān)督檢查，發(fā)現(xiàn)問題依法依規(guī)處理，保證中藥材質(zhì)量。
四、國家食品藥品監(jiān)督管理總局將會同有關(guān)部門積極推進實施中藥材gap制度,制訂完善相關(guān)配套政策措施，促進中藥材規(guī)范化、規(guī)?；?、產(chǎn)業(yè)化發(fā)展。
特此公告
